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Summary Although the presence of axillary node metastases in breast cancer is a key prognostic indicator and
may influence treatment decisions, a significant proportion of patients diagnosed as axillary node negative
(ANN) using standard histopathological techniques may have occult nodal metastases (OMs). A combination
of limited step-sectioning (4 x 100 /im intervals) and immunohistochemical staining (with cytokeratin
(MNF.116) and MUCI (BC2) antibodies) was used to detect OM in a retrospective series of 208 ANN
patients. OMs were found in 53 patients (25%), and both step-sectioning and immunohistochemical detection
significantly improved detection (P<0.05). Detection using BC2 (25%) was superior to MNF.116 (18%) and
haematoxylin and eosin (H&E) (8%). OMs were found in 51 patients using only the first and deepest sectioning
levels and BC2 staining. OMs were more frequently found in lobular (38%) than ductal carcinoma (25%), and
more frequently in women less than 50 years (41%) than in older women (19%). Univariate overall and
disease-free survival analyses showed that the presence, size and number of OM had prognostic significance as
did tumour size (disease-free only) and histological and nuclear grade (P>0.05). Cox multivariate proportional
hazard regression analyses showed that the presence and increasing size of OMs were significantly associated
with poorer disease-free survival, independently of other prognostic factors (P>0.05). However there was not a
significant independent association of the presence of occult metastases with overall survival (P=0.11). These
findings have important implications with regard to selection of ANN patients for adjuvant therapy.
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Several large clinical trials have illustrated the survival benefits
of adjuvant endocrine or chemotherapeutic treatments in
patients with axillary node-negative (ANN) breast cancer
(Fisher and Redmond, 1992; Stewart, 1992). However, as only
about 30% ofthis subgroup ofpatients will eventually develop
recurrent disease, adjuvant treatment of all node-negative
patients represents excessive treatment of a majority of these
patients. Prognostic factors are clearly required to help stratify
these patients into risk groups as the basis for decision-making
regarding the provision of adjuvant treatment. Factors
considered to have potential clinically useful prognostic
importance in ANN breast cancer include tumour size,
tumour grade, ploidy, presence of oestrogen receptors,
overexpression of oncogenes such as c-erbB-2 and epidermal
growth factor receptor (EGFR), altered expression of tumour-
suppressor genes such as p53 and Rbl, and increased
expression of molecules involved in invasion and metastasis
such as cathepsin D (for a review, see McGuire et al., 1992).
While all of these factors have been demonstrated to have
prognostic importance, no single variable clearly stratifies
patients into risk groups, and therefore clinical decisions must
be made giving consideration to multiple factors.
The presence of axillary node metastases is accepted as a
key prognostic indicator in breast cancer (Nemoto et al.,
1980), yet is has been recognised for some time that a
significant proportion of patients diagnosed as node negative
using standard histopathological techniques may in fact have
nodal metastases. However, the proportion of ANN patients
with these occult metastases, the best practical way of
detecting them, and the prognostic significance of these
metastases remain unclear. There are two main sources of
error in the current histopathological examination of axillary
lymph nodes for the detection of metastases. The first
involves sampling error attributable to the sectioning
procedure and is related to the size of the node, the
orientation of the node in the sectioning block, the size and
location of any metastases, and the number of sections
examined (Wilkinson and Hause, 1974). The second involves
microscopic misdiagnosis of sectioned metastases, which is
related to the size and location of the metastases and the
morphology of the lesions and surrounding nodal tissue.
Strategies for reducing sectioning error that have been
tested include macroscopic sectioning of large nodes before
blocking (de Mascarel et al., 1992) and serial or step-
sectioning through routinely prepared blocks [Wilkinson et
al., 1982; Friedman et al., 1988; International (Ludwig)
Breast Cancer Study Group, 1990]. Strategies for reducing
microscopic misdiagnosis that have been tested include using
immunohistochemical techniques to highlight metastases
(Wells et al., 1984). More recently, a technique using reverse
transcriptase-polymerase chain reaction (RT-PCR) to detect
expression of tumour-associated antigen mRNA extracted
from axillary nodes has been tested as an alternative to
histopathological examination (Noguchi et al., 1994).
However, using either serial sectioning or immunohistochem-
ical detection in isolation ignores the alternative source of
error in diagnosis. For example, in a Ludwig Breast Cancer
Study Group examination of lymph nodes from 921 patients
using a laborious serial sectioning procedure examining 36
sections from each block, only 9% of patients were found to
have metastases [International (Ludwig) Breast Cancer Study
Group, 1990]. This proportion is equal to or less than that
found by many trials using a more practical strategy of
immunohistochemical detection in a single section (Wells et
al., 1984; Trojani et al., 1987a; Raymond and Leong, 1989;
Galea et al., 1991; Byrne et al., 1992; Elson et al., 1993;
Hainsworth et al., 1993). Despite its apparently high
detection rate, immunohistochemical detection in a single
section ignores the reality of sampling error. A recent study
using a combination of step-sectioning and immunohisto-
chemical detection found metastases in 31% of 159 ANN
patients (Nasser et al., 1993).
The prognostic significance of occult metastases detected
by non-standard techniques remains contentious. In the
Ludwig Group study occult metastases detected by serial
sectioning were associated with significantly poorer overall
and disease-free survival [International (Ludgwig) Breast
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Cancer Study Group, 1990], although these findings differ
from those of two earlier large studies using similar
techniques (Wilkinson et al., 1982; Friedman et al., 1988).
Many of the studies using immunohistochemical detection of
micrometastases either do not address patient survival or
contain survival analyses based on small numbers of patients.
A summary of the results of six studies with survival analyses
is presented in Table I. It is evident that little consensus has
been obtained regarding the prognostic significance of
metastases detected in this way, although the two largest
studies show poorer survival in patients with metastases. We
present the results of a study designed to use both step-
sectioning and immunohistochemical detection of metastases
in order to reduce both sources of diagnostic error. Our aim
was to devise efficient yet practical techniques for the
detection of occult metastases and to assess the impact of
the presence of these metastases on disease-free and overall
survival.
Materials and methods
Patients
A total of 208 female patients with axillary node-negative
invasive carcinoma of the breast were enrolled retrospectively
in this study. All patients had undergone axillary clearance as
part of their surgical treatment at the Royal Brisbane
Hospital between January 1971 and July 1989 for invasive
carcinoma of the breast. Preparation of axillary nodes for
histological assessment was performed according to the
following principles outlined in Ackerman and Rosai
(1974). Small nodes were included without dissection, and
large nodes were multiply sliced before embedding. Nodes
were generally not processed singly but grouped according to
level in the axilla. However, some variation in adherence to
these methods could have occurred over the period of this
study. These procedures were performed before the develop-
ment of the current UK guidelines for pathological
assessment of axillary nodes. Axillary metastases were not
found in any of these patients on routine histopathological
assessment of a single haematoxylin and eosin (H&E)-stained
section from each block. Patients were included in the study
only after conforming with the following selection criteria: an
axillary dissection comprising at least five lymph nodes
(median= 12; range 5-32) and a minimum of 5 years
follow-up if not deceased of breast cancer (the median
follow-up of these patients was 92 months; range 59-235).
Patients in the study group had a median age of 59 years
(range 26-84).
One consultant histopathologist (RGW) reviewed the
original H&E-stained slide of all primary tumours to con-
firm the diagnosis. The tumours were graded according to the
Nottingham modification of the Bloom and Richardson
system (Elston and Ellis, 1991). Three tumours were not
graded because the infiltrating component was present as
multifocal minimal invasion in a larger area of in situ disease.
In 13 cases asynchronous bilateral primary breast tumours
occurred, and in five of these cases both primary tumours
were included in the study. However, for the purposes of
survival analysis, the patient was included using data for the
first tumour only. Patients who subsequently developed a
second primary with involvement of the contralateral axillary
lymph nodes were treated as censored observations for
survival analysis at the time of diagnosis of the second
primary. Two cases of synchronous bilateral ANN tumours
were included and each case was used as a single observation
for survival analysis. Data from 199 patients were included in
the survival analyses.
Serial sectioning
Each block containing lymph nodes was sectioned at four
levels each separated by 100 ,um, with serial sections from
each level being stained with H&E, antibody MNF. 116,
reactive with human cytokeratins 8,18, and 19 (Dako,
Carpinteria, CA, USA) and antibody BC2, reactive with
the MUCI epithelial mucin core protein (Xing et al., 1989,
1990) (a gift from Medical Innovations, Australia).
Immunohistochemistry
Sections were dewaxed and rehydrated to distilled water
through descending graded alcohols, then transferred to
0.1 M phosphate-buffered saline (PBS), pH 7.4. Sections to
be stained for cytokeratins were subjected to enzymatic
digestion using 0.1% trypsin, 0.1% calcium chloride in PBS
for 30 min at 37°C. Endogenous peroxidase activity was
quenched by incubating the sections in 0.3% hydrogen
peroxide, 18% methanol in PBS for 10 min. After thorough
washing in PBS, sections were immersed in 4% commercial
non-fat skim milk powder in PBS for 15 min to inhibit non-
specific antibody binding, before being transferred to a
humidified chamber and covered with 10% normal (non-
immune) goat serum for 20 min. Excess serum was decanted
from the sections and the primary antibody applied. The
antibodies were diluted 1 7000 in PBS containing 10% non-
immune sheep serum for BC2 mouse ascites and 1:100 for
MNF.1 16. The sections were incubated with the primary
antibody for 45 min at room temperature. Following this and
subsequent incubations, the sections were washed thoroughly
in three changes of PBS for 5 min each. In the case of BC2,
the first wash contained 1% v/v Triton X-100. Sections for
cytokeratins were then incubated for 30 min with prediluted
biotinylated goat anti-mouse immunoglobulin buffer (Zymed,
San Francisco, CA USA), then streptavidin-biotin-horse-
radish peroxidase conjugate (Zymed) diluted 1: 20 in PBS for
15 min. Sections being stained with BC2 were subsequently
incubated with biotinylated sheep anti-mouse immunoglobu-
lin (Amersham Australia, Sydney, Australia) diluted 1: 150 in
PBS followed by a 1:150 dilution in PBS of streptavidin-
horseradish peroxidase (Amersham). Antigenic sites were
revealed by incubating sections in 0.05% 3,3'-diaminobenzene
in 0.1 M Tris-buffered saline with hydrogen peroxide as
substrate. After washing in gently running tap water, the
sections were counterstained with haematoxylin, dehydrated
through graded alcohols, cleared in xylene, and mounted with
DePeX. Sections of human primary breast cancer were run
with each batch of immunohistochemical stains to act as
positive controls.
Table I Previous studies of survival in 'axillary node-negative' breast cancer patients with occult axillary node metastases detected using
immunohistochemical techniques
Per cent with
Reference Histological types Number ofpatients metastases Survival ofpatients with metastases
Trojani et al. (1987b) ILC 102 41 No difference
Trojani et al. (1987a) IDC 122 11 Poorer OS and DFS
Galea et al. (1991) All 98 9 No difference
Elson et al. (1993) IDC 97 21 No difference
Hainsworth et al. (1993) All 343 12 Poorer DFS for > I node involved
Nasser et al. (1993) All, SS 150 31 Poorer DFS for large metastases
ILC, infiltrating lobular carcinoma; IDC, infiltrating ductal carcinoma; OS, overall survival; DFS, disease-free survival, SS; plus step-sectioning.$"- Occuft metastases in node-negative breast cancer
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Interpretation of results
All prepared sections were coded and clinical information
was withheld from the investigators until the outcome of a
case was determined. H&E preparations were reviewed by
two pathologists (RGW and MCC) while immunohistochem-
ical stains were screened by two research scientists familiar
with immunohistology (MAM and MDW). In the event that
a positive result was recorded for any stain all sections from
that block were subject to a consensus review by all
participants. When an occult metastasis was detected,
measurement of its maximum dimension was made using a
standard graticule calibrated using a stage micrometer and
the location of the deposit was classified as being in the
capsule only, in the capsule and substance of the node, or in
the nodal parenchyma only.
a
c
Statistical analyses
Chi-squared tests were used to test for differences in
proportions of patients with metastases detected between
different patient groups and between different detection
methods. Kaplan-Meier survival statistics were generated
for each of the prognostic variables and differences in
univariate survival were assessed using the log-rank test.
Those variables with prognostic significance in univariate
analyses were then combined in multivariate proportional
hazards regression analyses to assess their independence as
prognostic indicators. Statistics were performed using the
SAS 6.04 and SPSS programs.
b
d
e f
Figure 1 Examples of occult metastases detected by immunohistochemical techniques. Capsular metastasis from an infiltrating
ductal carcinoma stained with H&E (a) and with the BC2 antibody directed against the MUCI mucin (b). Large metastasis of
scattered tumour cells from an infiltrating lobular carcinoma stained with H&E (c) with the MNF.116 antibody directed against
cytokeratins 8, 18 and 19 (d). Solid metastasis in the nodal parenchyma from an infiltrating ductal carcinoma showing detection
using staining with the BC2 antibody (e) but not using staining with the MNF.116 antibody (f). Scale bars = 100gim.Occult metastases in node-negative breast cancer
MA McGuckin et al
Results
Detection of metastases
Using a combination of step-sectioning and immunohisto-
chemical detection, occult metastases were found in the
lymph nodes from 53 of 208 cases (25%) of apparently node-
negative breast cancer. Examples of these metastases are
shown in Figure 1. Most metastases (28, 53%) were confined
to the capsule or subcapsular space (Figure la and b) with 13
(25%) confined to the node parenchyma and 12 (23%)
involving both the subcapsular space and nodal parenchyma.
Many metastases in the nodal parenchyma presented as
scattered tumour cells rather than solid metastases (Figure Ic
and d). Seven of the nine cases with large scattered deposits
(>1 mm diameter) in the nodal parenchyma were infiltrating
lobular carcinoma (ILC) (24% of cases of this histological
type) compared with only two ofinfiltrating ductal carcinoma
(IDC) (1% of these cases). The number of nodes involved
and the size of metastases are detailed in Tables II and III
respectively. In most cases (75%) only one node was involved
and in 79% of cases the metastases were less than 1 mm in
diameter. The detection rates in cases classified according to
histological type, tumour size, histological grade, menopausal
status and age are shown in Table IV. Occult metastases were
more frequently found in premenopausal and younger
women, and in patients with larger primary tumours. There
was also a trend toward a higher frequency of occult
metastases in ILC than in IDC, and only one of 16 cases
of other histological type had occult metastases detected.
The number of cases with metastases detected using each
of the staining techniques and each of the four sectioning
levels are detailed in Table V. Detection with either antibody
was significantly superior to detection with H&E-stained
sections at all sectioning levels (P<0.05). The overall
proportion of cases with occult metastases was greater using
detection with the BC2 monoclonal antibody reactive with
MUCI than using the cytokeratin-reactive antibody
MNF.116, although this difference just failed to reach
statistical significance (0.05 <P<0.06). Metastases detected
in 15 patients using BC2 were not detected using MNF.116,
but only in one case was a metastasis detected in a patient
using MNF.116 but not with BC2. Reappraisal of the
MUCI-positive/cytokeratin-negative metastases showed
these stained either very weakly or not at all with
MNF.116 (Figure le and f). Interestingly, the number of
cases with metastases detected using either immunohisto-
chemical technique was equivalent at each sectioning level but
the number ofcases detected at deeper levels was significantly
greater when using H&E detection (level 1 vs level 4,
P<0.02). Combining data from all four levels gave an
increased detection rate over that for level one alone for all
staining techniques, although this difference was not
statistically significant for cytokeratin detection. It can be
seen in Table V that combining levels one and four (the first
Table II Number of positive nodes in 53 cases of axillary node-
negative breast cancer with metastases detected using a combination
of immunohistochemical detection and step-sectioning
Number ofnodes involved
1 2 3 4 5
No. of cases 40 8 2 2 1
Per cent 75 15 4 4 2
and deepest levels) gave virtually identical detection rates to
those obtained using all four levels for each of the three
staining techniques.
Specificity of immunohistochemical detection
All immunohistochemically detected cells were checked for
morphological features consistent with adenocarcinoma
before verification as a metastatic deposit. In two cases
isolated immunohistochemically detected cells were present
that were unable to be confirmed as tumour cells and were
therefore considered equivocal and these nodes were classified
as being tumour free. In several cases isolated normal
lymphoid cells were positive using the BC2 antibody but
these cells were easily recognised as such and after
confirmation of this finding by consensus review by two
pathologists (MCC and RGW) were disregarded. Five benign
naevi were detected in this series; none of these were positive
for either cytokeratins or MUC1. One benign epithelial
inclusion was detected and this was positive for both MUCI
and cytokeratins. Cytokeratin staining of this inclusion was
indistinguishable from that of tumour cells (intense
cytoplasmic staining) but MUCI was present only as weak
luminal membrane staining and this normal pattern of
expression, along with morphological features and the
demonstration of surrounding smooth muscle actin, facili-
tated the diagnosis of a benign inclusion.
Survival analyses
Univariate survival analyses based on the presence/absence of
metastases, number of nodes involved, size of metastases,
histological type, tumour size, histological and nuclear grade,
age and microvascular invasion are shown in Table VI.
Patients with occult metastases had significantly shorter
disease-free and overall survival. In addition, it appeared
that the number of nodes involved and the size of metastases
had prognostic significance for disease-free survival (Figure
Table IV Detection of metastases using a combination of
immunohistochemical detection and step-sectioning in 208 cases of
axillary node-negative breast cancer classified according to histolo-
gical type, tumour size, histological grade, menopausal status and age
Number of cases
Number with metastases
Classification of cases (%) x2, p
Histological type
Ductal carcinoma 163 41 (25) 5.49, 0.064 (NS)
Lobular carcinoma 29 11 (38)
Other 16 1 (6)
Tumour size
<20 mm 130 26 (20) 5.48, 0.019
>20 mm 78 27 (35)
Histological grade
1 62 15 (24) 2.58, 0.28 (NS)
2 93 28 (30)
3 50 9(18)
Menopausal status
Pre- and peri- 50 20 (40) 7.38, 0.007
Post- 150 31 (21)
Age
<50 years 64 26 (41) 11.17, <0.001
> 50 years 144 27 (19)
Statistics: x2 and P-value shown; NS, not significant.
Table III Size of metastases detected in 53 cases of axillary node-negative breast cancer using a combination of immunohistochemical detection
and step-sectioning
Diameter of metastasis
Small scattered deposits <250 gm 250-500 gim 501-1000 gim > 1000 Pm
Number of cases 6 22 7 7 11
Per cent 11 42 13 13 214 Occult metastases in node-negative breast cancer
1% MA McGuckin et al
2a-d). No significant differences in survival were seen based
on the location of metastases within the node. Separate
survival analyses were also performed for patients with ductal
and lobular carcinomas because of the different rates of
positivity and presentation of metastases between these
histological types. Disease-free survival analyses showed the
prognostic importance of occult metastases in IDC but not in
ILC (not shown), although it must be stressed that the ILC
group was small (n = 26). Only one of 16 cases of non-IDC,
non-ILC had a metastasis detected and this patient died of
breast cancer, she being the only patient of this group who
has developed recurrent disease to date. Because of the high
rate of detection of metastases in younger women, separate
analyses were also performed for younger (<50) and older
(s< 50) women. Overall survival analyses showed a trend for
poorer survival in younger women with occult metastases but
not in older women. However, this trend was reversed in
disease-free survival analysis (not shown).
Tumour size and histological and nuclear grade were also
of prognostic importance; these variables were combined
along with patient age and histological type with data
concerning detection of occult metastases in multivariate
proportional hazards regression analyses. The presence of
metastases (P=0.093), their size (P=0.221) and the number
of nodes involved (P=0.244) were not shown to be
statistically significant independent predictors of overall
survival at the 95% level. However, the presence (P=0.036)
and increasing size of metastases (P =0.037) were significantly
associated with poorer disease-free survival, independently of
other considered prognostic factors. Relative hazard rates for
the model using presence/size of metastases are shown in
Table VII. A simple index was constructed using the sum of
coded data from tumour size (0, <20 mm diameter; 1,
>20 mm), histological grade (0, grade 1; 1, grades 2 and 3)
and presence/size of occult metastases (0, absent; 1,
<0.5 mm; 2, >0.5 mm). Figure 3 illustrates the progres-
sively poorer disease-free survival of patients with increasing
index scores. Particularly striking was the completely disease-
free survival of the 35 patients with small, low-grade tumours
and no occult metastases (index score 0).
Discussion
The results of this study confirmed the predicted sources of
error in standard pathological assessment of axillary lymph
nodes with both immunohistochemical detection and step-
sectioning resulting in increased detection of metastases. A
technique which is practical and relatively inexpensive to
implement, that is obtaining two sections 300 gm apart and
staining with one antibody, resulted, in this study, in the
detection of occult metastases in 25% of apparently node-
negative patients. The presence of these metastases was
associated with poorer disease-free and overall survival, and
was of independent prognostic significance for disease-free
survival to other significant variables including tumour size
and histological grade. Furthermore, we have demonstrated
that metastases in these immunohistochemical sections can be
detected by adequately trained scientific staff, which would
minimise the workload of specialist pathologists and there-
fore reduce the cost of implementing such procedures.
The detection of occult metastases in 25% of cases of
ANN breast cancer is higher than that found in most
previous studies designed to detect these metastases
[Wilkinson et al., 1982; Wells et al., 1984; Trojani et al.,
1987a; Raymond and Leong, 1989; International (Ludwig)
Breast Cancer Study Group, 1990; Nio et al., 1990; Galea et
al., 1991; Byrne et al., 1992; Elson et al., 1993; Hainsworth et
al., 1993]. However, the only other study to simultaneously
address both sources of error in the standard histopatholo-
gical technique found metastases in 31% of 159 ANN
patients (Nasser et al., 1993). Furthermore, the findings in
the current study of metastases in 8% of cases using four
sectioning levels and H&E detection and 13% of cases using
immunohistochemical detection of cytokeratins in a single
section are similar to those data found in earlier studies using
comparable techniques.
The superior detection of metastases using the MUC1-
reactive antibody BC2 compared with the cytokeratin
antibody MNF.116 was unexpected. Two previous studies
comparing two different cytokeratin antibodies (CAM5.2 and
AE1/AE3) with two different MUCI antibodies (NCRC11
and DF3) found the cytokeratin antibodies to be at least as
good as the MUC1 antibodies for the detection of metastatic
deposits (Galea et al., 1991; Elson et al., 1993). The decreased
staining efficiency with the cytokeratin antibody in the
present study appears to be related to loss of expression of
cytokeratins or to difficulty of detection as, unlike mucin
detection with BC2, the detection with MNF.116 requires a
trypsinisation step to reveal these epitopes. Positive control
breast cancer sections were included in each staining run and
were always positive using MNF. 116. Staining of primary
Table V Number of cases with occult metastases detected at each of four 100 gim sectioning levels and with each of three
staining techniques in 208 cases of axillary node-negative breast cancer
Individual sectioning level Combined sectioning levels
Stain 1 2 3 4 1, 2, 3 and 4 1 and 2 1 and 3 1 and 4
H&E 7 11 11 13 17 11 12 17
MNF.116 27 26 25 25 37 32 33 33
BC2 36 34 35 38 52 40 44 51
Totala 38 37 37 39 53 43 47 51
aPositive using at least one stain.
Table VI Univariate survival analyses in patients with axillary node-negative breast cancer separated on the basis of detection of metastases
using a combination of immunohistochemical detection and step-sectioning, histological type, tumour size and histological and nuclear grade
Disease-free survival Overall survival
Variable Classifications X2 p %2 P
Occult metastases Absent, present* 7.27 0.007 5.31 0.021
Number of nodes involved 0, 1*, > 1* 7.28 0.007 4.53 0.033
Size of occult metastases None, <0.5 mm*, >0.5 mm* 8.80 0.003 5.08 0.024
Histological type Ductal, lobular, other 0.42 0.52 (NS) 0.99 0.32 (NS)
Tumour size <20 mm, >20 mm* 7.47 0.006 3.23 0.07 (NS)
Histological grade 1, 2*, 3* 4.72 0.030 4.77 0.029
Nuclear grade 1, 2*, 3* 7.03 0.008 8.65 0.003
Age <50 years, >50 years 0.88 0.39 (NS) 2.26 0.13 (NS)
Microvascular invasion Absent, present 0.35 0.55 (NS) 0.22 0.64 (NS)
The classifications with poorer survival are marked with an asterisk. Statistics: log-rank text, x2 and P-value shown; NS, not significant.Occult metastases in node-negative breast cancer
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Figure 2 Disease-free (a,c) and overall (b,d) survival curves for 199 axillary node-negative breast cancer patients classified
according to the number of nodes with occult metastases (a,b) and the size of occult metastases (c,d). The tables at the base of each
graph show the number of disease-free or surviving and non-censored patients at the end of each 20 month survival interval.
Statistics: Log-rank test, x2 and P-value shown.
tumours with MNF.116 has shown some evidence for both of
these phenomenon using adjacent normal breast glands as a
positive control. In some specimens the staining of primary
tumours was weak and irregular as was staining of normal
glands, whereas in others, staining in tumours was weak or
absent despite strong reactivity in adjacent normal glands.
However, it must also be noted that due to the complex
nature of the MUCI mucin and the influence of glycosylation
on the reactivity of antibodies reactive with the MUCI core
protein, the reactivity of different antibodies with cancer-
associated mucin can vary considerably, and the BC2
antibody may be superior to other antibodies previously
used (McGuckin et al., 1995).
The higher rate of detection of occult metastases in
younger patients found in the present series is consistent with
the higher rate of detection reported in the Ludwig group
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Table VII Relative hazard rates for potential prognostic variables
associated with disease-free and overall survival determined using
Cox multivariate proportional hazards regression analyses
Variable
Presencelsize of metastases
Absent
<0.5 mm
>0.5 mm
Histological grade
1
2
3
Tumour size
<20 mm
>20 mm
Nuclear grade
1
2
3
Relative hazard rates
Disease-free Overall
survival survival
1.0
1.64 (0.73, 3.67)
3.72 (1.43, 9.69)
1.0
3.86 (1.11, 13.40)
2.68 (0.63, 11.34)
1.0
1.99 (1.02, 3.88)
1.0
0.67 (0.19, 2.37)
1.24 (0.33, 4.67)
1.0
1.91 (0.73, 5.05)
2.62 (1.43, 9.12)
1.0
5.07 (0.86, 29.96)
2.89 (0.41, 20.17)
1.0
1.53 (0.65, 3.59)
1.0
0.90 (0.14, 5.68)
2.12 (0.33, 13.54)
95% confidence intervals are shown in parenthesis.
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Figure 3 Disease-free survival curve for axillary node-negative
breast cancer patients classified according to the score of an index
based on tumour size, histological grade and the presence/size of
occult metastases. The table at the base of the graph shows the
number of disease-free and non-censored patients at the end of
each 20 month survival interval. Statistics: log-rank test, x2 and
P-value shown.
study (12% in women less than 50 vs 7% in women older
than 50), [International (Ludwid) Breast Cancer Study
Group, 1990]. A greater detection in younger women is
consistent with a higher rate of detection of nodal metastases
in younger women using standard histopathological techni-
ques and is probably related to the generally more aggressive
nature of breast cancers in these women. However, no
relationship between metastases and age was demonstrated in
two large studies using immunohistochemical detection
(Hainsworth et al., 1993; Nasser et al., 1993). The higher
rate of detection of occult metastases in lobular compared
with ductal carcinoma confirms the findings of Trojani et al.,
(1987a). Metastatic lobular carcinoma appears more likely to
present as occult deposits of scattered cells within the nodal
parenchyma than metastatic ductal carcinoma. In the present
study these scattered deposits were often quite large and they
obviously present a diagnostic difficulty using H&E due to
morphological similarities with surrounding cells in the
lymph node. Consistent with this hypothesis, the large
Ludwig group study based on serial sectioning and H&E
detection showed an equivalent rate of detection of
metastases from IDC and ILC.
The results of this study clearly show poorer disease-free
and overall survival in patients with occult metastases. These
data also support the findings of previous studies using
immunohistochemical detection that showed that the size of
occult metastases and number of nodes involved have
prognostic importance (Hainsworth et al., 1993; Nasser et
al., 1993). Although the number of cases of ILC in this study
is quite small, the survival results from this group do not
contradict the findings of a previous study with more patients
with ILC that found that occult metastases had little
prognostic significance in ILC (Trojani et al., 1987a). The
differences in survival between patients with ILC and IDC
who also have occult metastases may reflect biological
differences consistent with their different patterns of
metastatic spread characterised by Harris et al. (1984). The
independent significance of the presence/size of occult
metastases suggests that this factor could be combined with
other more traditionally used prognostic factors when
assessing the risk of recurrence or death of patients with
apparently node-negative breast cancer. The simple index
created from presence/size of occult metastases, histological
grade and tumour size suggests that these patients could well
be stratified into prognostic groups that may be used for
determining and tailoring adjuvant systemic treatments in
this group of patients traditionally regarded as node negative
and in whom the selection ofpatients truly requiring systemic
treatment has formerly been difficult. It may be that in the
future that such an index including detection of occult
metastases could be combined with biological markers of
poor prognosis such as alterations in tumour-suppressor
genes and increased expression of oncogenes. We shall be
examining the associations of such factors in these patients in
the near future. Detection of metastatic tumour cells in bone
marrow of breast cancer patients is now also feasible and
may have prognostic significance (Cote et al., 1991;
Dearnaley et al., 1991), and could also be combined into a
risk index.
We have demonstrated a high rate of occult metastases in
patients with ANN breast cancer and have shown that these
metastases can be detected using practical and affordable
variations to standard histopathological techniques. The
presence of these metastases is an independent indicator of
poor prognosis and therefore should be considered for
inclusion into indices used to stratify ANN patients into
risk groups for consideration for adjuvant therapy.
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